Global Medicine for the Treatment of Advanced Thyroid Cancer Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Thyroid cancer is the most common endocrine tumor. Four targeted agents (vandetanib, cabozantinib, sorafenib, and lenvatinib) have attained regulatory approval for advanced thyroid cancer, and several other related agents are now commonly used off-label as first- and second-line treatments for selected patients.
Medicine for the Treatment of Advanced Thyroid Cancer report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Medicine for the Treatment of Advanced Thyroid Cancer market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Combination therapy and Solo Medication are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Medicine for the Treatment of Advanced Thyroid Cancer industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Medicine for the Treatment of Advanced Thyroid Cancer key manufacturers include Bayer, AstraZeneca, Sanofi, Exelixis Inc., Ipsen Pharma and Eisai Inc, etc. Bayer, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
Medicine for the Treatment of Advanced Thyroid Cancer can be divided into Cabozantinib, Sorafenib, Vandetanib and Lenvatinib, etc. Cabozantinib is the mainstream product in the market, accounting for % sales share globally in 2022.
Medicine for the Treatment of Advanced Thyroid Cancer is widely used in various fields, such as Combination therapy and Solo Medication, etc. Combination therapy provides greatest supports to the Medicine for the Treatment of Advanced Thyroid Cancer industry development. In 2022, global % sales of Medicine for the Treatment of Advanced Thyroid Cancer went into Combination therapy filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Medicine for the Treatment of Advanced Thyroid Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bayer
AstraZeneca
Sanofi
Exelixis Inc.
Ipsen Pharma
Eisai Inc
Segment by Type
Cabozantinib
Sorafenib
Vandetanib
Lenvatinib
Combination therapy
Solo Medication
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Medicine for the Treatment of Advanced Thyroid Cancer market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Medicine for the Treatment of Advanced Thyroid Cancer, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Medicine for the Treatment of Advanced Thyroid Cancer industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Medicine for the Treatment of Advanced Thyroid Cancer in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Medicine for the Treatment of Advanced Thyroid Cancer introduction, etc. Medicine for the Treatment of Advanced Thyroid Cancer Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Medicine for the Treatment of Advanced Thyroid Cancer market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Medicine for the Treatment of Advanced Thyroid Cancer report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Medicine for the Treatment of Advanced Thyroid Cancer market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Combination therapy and Solo Medication are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Medicine for the Treatment of Advanced Thyroid Cancer industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Medicine for the Treatment of Advanced Thyroid Cancer key manufacturers include Bayer, AstraZeneca, Sanofi, Exelixis Inc., Ipsen Pharma and Eisai Inc, etc. Bayer, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
Medicine for the Treatment of Advanced Thyroid Cancer can be divided into Cabozantinib, Sorafenib, Vandetanib and Lenvatinib, etc. Cabozantinib is the mainstream product in the market, accounting for % sales share globally in 2022.
Medicine for the Treatment of Advanced Thyroid Cancer is widely used in various fields, such as Combination therapy and Solo Medication, etc. Combination therapy provides greatest supports to the Medicine for the Treatment of Advanced Thyroid Cancer industry development. In 2022, global % sales of Medicine for the Treatment of Advanced Thyroid Cancer went into Combination therapy filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Medicine for the Treatment of Advanced Thyroid Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bayer
AstraZeneca
Sanofi
Exelixis Inc.
Ipsen Pharma
Eisai Inc
Segment by Type
Cabozantinib
Sorafenib
Vandetanib
Lenvatinib
Segment by Application
Combination therapy
Solo Medication
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Medicine for the Treatment of Advanced Thyroid Cancer market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Medicine for the Treatment of Advanced Thyroid Cancer, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Medicine for the Treatment of Advanced Thyroid Cancer industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Medicine for the Treatment of Advanced Thyroid Cancer in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Medicine for the Treatment of Advanced Thyroid Cancer introduction, etc. Medicine for the Treatment of Advanced Thyroid Cancer Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Medicine for the Treatment of Advanced Thyroid Cancer market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices